Our client is a Top 10 pharmaceutical company with over $35B in annual revenues.
Client’s Need and Challenges
- Two years ago, it was estimated that there will be 30,280 new cases of Multiple Myeloma and an estimated 12,590 people will die of this disease annually. The client needed to better understand patients’ cost of care by patient segment, to better understand the treatment differences, and to inform its valuebased contracting team. The client also wanted to identify new Multiple Myeloma patients eligible for treatment.
- The oncology market is complex, with multiple therapies (biologic, oral and procedural) used in various treatment combinations. To define lines of therapy within the patient journey, an extensive set of clinical rules are required. Longitudinal patient-level data and advanced analytics are needed to establish adequate patient counts.
Our Approach and Methodology
- EXL developed a Patient Care Gap model, assessed patients’ risk and impactability scores, and quantified Cost of Care.
- EXL analyzed patient demographic data (age, gender, geography), utilization metrics (inpatient admissions, length of stay, emergency room visits, outpatient visits, PCP visits, and specialist visits), and comorbid conditions limited to chronic conditions, including but not limited to diabetes, arthritis, asthma, chronic obstructive pulmonary disease (COPD), heart disease, and obesity.
ANTICIPATED RESULTS & UTILITY
- Deliverables included a Line of Therapy (LoT) analysis, Treatment Segments, and scored Cost of Care (CoC) results for each LoT and for each treatment segment within each LoT.
- The client will use the results to target new patient types, determine patient distribution across treatment segments, better understand the patient universe and established lines of therapy for commercial and health economics purposes.
Written by EXL Health Team